Loading clinical trials...
Loading clinical trials...
Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Conditions
Interventions
Cabozantinib
Locations
6
United States
Children's Hospital of Alabama/UAB
Birmingham, Alabama, United States
Children's Hospital of Colorado
Aurora, Colorado, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Primary Children's Hospital
Salt Lake City, Utah, United States
Start Date
July 20, 2022
Primary Completion Date
July 1, 2026
Completion Date
December 1, 2029
Last Updated
August 12, 2025
NCT05039801
NCT04704661
NCT06066138
NCT07479732
NCT03715933
NCT07156565
Lead Sponsor
Nationwide Children's Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions